UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

Example Bundle: Maxilene-40mg-cream-SE-AJ-MPD-BBDL

Maxilene 40 mg/g Kräm

MPID: SE-100016626-00050469
EURDID: 10933

Full name: Maxilene 40 mg/g Kräm

- Invented Name Part: Maxilene

- Strength part: 40 mg/g

- Pharmaceutical dose form part: Kräm

Name usage: Swedish (Kingdom of Sweden)

Authorised dose form: Cream

Legal status of supply: Medicinal product subject to prescription exempt for some pack sizes

Domain: Human use

Resource status: Current

Product classification:

  • 100000095332 lidocaine

Marketing Authorisation 1 of 1

Authorisation number: 50469

Region: Kingdom of Sweden

Marketing authorisation holder: Ferndale Laboratories Limited

Identifier:

  • LOC-100025420

Status: Valid (2015-12-16)

Package 1 of 1

PCID:

Description:
Tub, 1 x 30 g

Marketing status:

  • Kingdom of Sweden: Marketed

Pack size:

  • 1 tube

Package: 1 Box (Cardboard)

Containing:

Package: 1 Tube (Aluminium)

Containing: 30 gram(s)

Manufactured Item

Dose form: Cream

Unit of presentation: Tube

Ingredient

Role: Active

Substance: Lidocaine

Concentration strength: 40 milligram(s) / 1 gram(s)

Reference strength:
Lidocaine 40 milligram(s) / 1 gram(s)

Administrable Product (1 of 1)

Dose form: Cream

Unit of presentation:

Route of administration:

  • Cutaneous use

Ingredients:

Ingredient

Role: Active

Substance: Lidocaine

Concentration strength: 40 milligram(s) / 1 gram(s)

Reference strength:
Lidocaine 40 milligram(s) / 1 gram(s)